SEARCH

SEARCH BY CITATION

References

  • 1
    Fiore MC, Jaén CR, Baker TB, Bailey WC, Benowitz NL, Curry SJ, Dorfman SF, Froelicher ES, Goldstein MG, Healton CG, Henderson PN, Heyman RB, Koh HK, Kottke TE, Lando HA, Mecklenburg RE, Mermelstein RJ, Mullen PD, Orleans CT, Robinson L, Stitzer ML, Tommasello AC, Villejo L, Wewers ME. Treating Tobacco Use and Dependence: 2008 Update. Clinical Practice Guideline. Rockville, MD: U.S. Department of Health and Human Services, Public Health Service, 2008; updated May 2008. Available at http://www.ncbi.nlm.nih.gov.gate2.inist.fr/books/NBK12193 (last accessed 1 October 2010).
  • 2
    Centers for Disease Control and Prevention (CDC). Annual smoking-attributable mortality, years of potential life lost, and productivity losses−United States, 1997–2001. MMWR Morb Mortal Wkly Rep 2005; 54: 625628.
  • 3
    The Clinical Practice Guideline Treating Tobacco Use and Dependence 2008 Update Panel, Liaisons, and Staff. A clinical practice guideline for treating tobacco use and dependence: 2008 update. A U.S. Public Health Service report. Am J Prev Med 2008; 35: 158176.
  • 4
    WHO report on the global tobacco epidemic: warning about the dangers of tobacco. 2011. Available at http://whqlibdoc.who.int/hq/2011/WHO_NMH_TFI_11.3_eng.pdf (last accessed 27 June 2012).
  • 5
    Jha P. Avoidable global cancer deaths and total deaths from smoking. Nat Rev Cancer 2009; 9: 655664.
  • 6
    Doll R, Peto R, Boreham J, Sutherland I. Mortality in relation to smoking : 50 years'observation on male British doctors. Br Med J 2004; 328: 1519.
  • 7
    Bjartveit K, Tverdal A. Health consequences of sustained smoking cessation. Tob Control 2009; 18: 197205.
  • 8
    Raw M. Framework Convention on Tobacco Control (FCTC) Article 14 guidelines: a new era for tobacco dependence treatment. Addiction 2011; 106: 20552057.
  • 9
    Benowitz NL. Nicotine addiction. N Engl J Med 2010; 362: 22952303.
  • 10
    Shiffman S, Scharf DM, Shadel WG, Gwaltney CJ, Dang Q, Paton SM, Clark DB. Analyzing milestones in smoking cessation: illustration in a nicotine patch trial in adult smokers. J Consult Clin Psychol 2006; 74: 276285.
  • 11
    West R, McNeill A, Britton J, Bauld L, Raw M, Hajek P, Arnott D, Jarvis M, Stapleton J. Should smokers be offered assistance with stopping? Addiction 2010; 105: 18671869.
  • 12
    Chapman S, Wakefield M. Smoking cessation strategies. BMJ 2012; 344: e1732.
  • 13
    Chapman S, MacKenzie R. The global research neglect of unassisted smoking cessation: causes and consequences. PLoS Med 2010; 7: e1000216.
  • 14
    Chapman S. The inverse impact law of smoking cessation. Lancet 2009; 373: 701703.
  • 15
    Richard P, West K, Ku L. The return on investment of a Medicaid tobacco cessation program in Massachusetts. PLoS ONE 2012; 7: e29665.
  • 16
    Taylor M, Leonardi-Bee J, Agboola S, McNeill A, Coleman T. Cost effectiveness of interventions to reduce relapse to smoking following smoking cessation. Addiction 2011; 106: 18191826.
  • 17
    Mahmoudi M, Coleman CI, Sobieraj DM. Systematic review of the cost-effectiveness of varenicline vs. bupropion for smoking cessation. Int J Clin Pract 2012; 66: 171182.
  • 18
    Aubin HJ, Karila L, Reynaud M. Pharmacotherapy for smoking cessation: present and future. Curr Pharm Des 2011; 17: 13431350.
  • 19
    Stead LF, Bergson G, Lancaster T. Physician advice for smoking cessation. Cochrane Database Syst Rev 2008; (2): CD000165.
  • 20
    Lancaster T, Stead LF. Individual behavioural counselling for smoking cessation. Cochrane Database Syst Rev 2005; (2): CD001292.
  • 21
    Etter JF, Schneider NG. An internet survey of use, opinions and preferences for smoking cessation medications: nicotine, varenicline, and bupropion. Nicotine Tob Res 2013; 15: 5968.
  • 22
    Fant RV, Buchhalter AR, Buchman AC, Henningfield JE. Pharmacotherapy for tobacco dependence. Handb Exp Pharmacol 2009; 192: 487510.
  • 23
    U.S. Department of Health and Human Services. The Health Consequences of Smoking: Nicotine Addiction: A Report of the Surgeon General. Rockville, MD: U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control, Center for Health Promotion and Education, Office on Smoking and Health, 1988. Available at http://profiles.nlm.nih.gov/NN/B/B/Z/D/_/nnbbzd.pdf (last accessed 1 October 2010).
  • 24
    Edens E, Massa A, Petrakis I. Novel pharmacological approaches to drug abuse treatment. Curr Top Behav Neurosci 2010; 3: 343386.
  • 25
    West RJ, Jarvis MJ, Russell MA, Carruthers ME, Feyerabend C. Effect of nicotine replacement on the cigarette withdrawal syndrome. Br J Addict 1984; 79: 215219.
  • 26
    Foulds J, Burke M, Steinberg M, Ziedonis DM, Williams JM. Advances in pharmacotherapy for tobacco dependence. Expert Opin Emerg Drugs 2004; 9: 3953.
  • 27
    Berlin I. Therapeutic strategies to optimize the efficacy of nicotine replacement therapies. COPD 2009; 6: 272276.
  • 28
    Buchhalter AR, Fant RV, Henningfield JE. Novel pharmacological approaches for treating tobacco dependence and withdrawal: current status. Drugs 2008; 68: 10671088.
  • 29
    Tonnesen P, Lauri H, Perfekt R, Mann K, Batra A. Efficacy of a nicotine mouth spray in smoking cessation: a randomised, double blind trial. Eur Respir J 2012; 40: 548554.
  • 30
    D'Orlando KJ, Fox BS. Tolerability and pharmacokinetics of single and repeated doses of nicotine with The Straw, a novel nicotine replacement product. Nicotine Tob Res 2004; 6: 6370.
  • 31
    Westman EC, Tomlin KF, Perkins CE, Rose JE. Oral nicotine solution for smoking cessation: a pilot tolerability study. Nicotine Tob Res 2001; 3: 391396.
  • 32
    Nides M. Update on pharmacologic options for smoking cessation treatment. Am J Med 2008; 121: (4 Suppl. 1): S2031.
  • 33
    Stead LF, Perera R, Bullen C, Mant D, Lancaster T. Nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev 2012; (1): CD000146.
  • 34
    Sweeney CT, Fant RV, Fagerstrom KO, McGovern JF, Henningfield JE. Combination nicotine replacement therapy for smoking cessation: rationale, efficacy and tolerability. CNS Drugs 2001; 15: 453467.
  • 35
    Mills EJ, Wu P, Lockhart I, Thorlund K, Puhan M, Ebbert JO. Comparisons of high-dose and combination nicotine replacement therapy, varenicline, and bupropion for smoking cessation: a systematic review and multiple treatment meta-analysis. Ann Med 2012; 44: 588589.
  • 36
    Bullen C, Howe C, Lin RB, Grigg M, Laugesen M, McRobbie H, Glover M, Walker N, Wallace-Bell M, Whittaker R, Rodgers A. Pre-cessation nicotine replacement therapy: pragmatic randomized trial. Addiction 2010; 105: 14741483.
  • 37
    Shiffman S, Ferguson SG. Nicotine patch therapy prior to quitting smoking: a meta-analysis. Addiction 2008; 103: 557563.
  • 38
    Lindson N, Aveyard P. An updated meta-analysis of nicotine preloading for smoking cessation: investigating mediators of the effect. Psychopharmacology (Berl) 2011; 214: 579592.
  • 39
    Lingford-Hughes AR, Welch S, Peters L, Nutt DJ. BAP updated guidelines: evidence-based guidelines for the pharmacological management of substance abuse, harmful use, addiction and comorbidity: recommendations from BAP. J Psychopharmacol 2012; 26: 899952.
  • 40
    Hughes JR, Cummings KM, Foulds J, Shiffman S, West R. Effectiveness of nicotine replacement therapy-a rebuttal. Addiction 2012; 107: 15271528.
  • 41
    Alpert HR, Connolly GN, Biener L. A prospective cohort study challenging the effectiveness of population-based medical intervention for smoking cessation. Tob Control 2013; 22: 3237.
  • 42
    Aubin HJ, Farley A, Lycett D, Lahmek P, Aveyard P. Weight gain in smokers after quitting cigarettes: meta-analysis. BMJ 2012; 345: e4439.
  • 43
    Farley AC, Hajek P, Lycett D, Aveyard P. Interventions for preventing weight gain after smoking cessation. Cochrane Database Syst Rev 2012; (1): CD006219.
  • 44
    Aubin HJ, Luthringer R, Demazieres A, Dupont C, Lagrue G. Comparison of the effects of a 24-h nicotine patch and a 16-h nicotine patch on smoking urges and sleep. Nicotine Tob Res 2006; 8: 193201.
  • 45
    Staner L, Luthringer R, Dupont C, Aubin HJ, Lagrue G. Sleep effects of a 24-h versus a 16-h nicotine patch: a polysomnographic study during smoking cessation. Sleep Med 2006; 7: 147154.
  • 46
    Hajek P, Jackson P, Belcher M. Long-term use of nicotine chewing gum. Occurrence, determinants, and effect on weight gain. JAMA [Research Support, Non-U.S. Gov't]. 1988 Sep 16;260: 15931596.
  • 47
    Etter JF. Dependence on the nicotine gum in former smokers. Addict Behav 2009; 34: 246251.
  • 48
    Ferry LH. Non-nicotine pharmacotherapy for smoking cessation. Prim Care [Review]. 1999 Sep;26: 653669.
  • 49
    Wilkes S. The use of bupropion SR in cigarette smoking cessation. Int J Chron Obstruct Pulmon Dis 2008; 3: 4553.
  • 50
    Ascher JA, Cole JO, Colin JN, Feighner JP, Ferris RM, Fibiger HC, Golden RN, Martin P, Potter WZ, Richelson E, Sulser F. Bupropion : a review of its mechanism of antidepressant activity. J Clin Psychiatry 1995; 56: 395401.
  • 51
    Slemmer JE, Martin BR, Damaj MI. Bupropion is a nicotinic antagonist. J Pharmacol Exp Ther 2000; 295: 321327.
  • 52
    Aubin HJ, Lebargy F, Berlin I, Bidaut-Mazel C, Chemali-Hudry J, Lagrue G. Efficacy of bupropion and predictors of successful outcome in a sample of French smokers: a randomized placebo-controlled trial. Addiction 2004; 99: 12061218.
  • 53
    Hughes JR, Stead LF, Lancaster T. Antidepressants for smoking cessation. Cochrane Database Syst Rev 2007; (1): CD000031.
  • 54
    Mooney ME, Sofuoglu M. Bupropion for the treatment of nicotine withdrawal and craving. Expert Rev Neurother 2006; 6: 965981.
  • 55
    Aubin HJ. Tolerability and safety of sustained-release bupropion in the management of smoking cessation. Drugs 2002; 62: (Suppl. 2): 4552.
  • 56
    Tonstad S, Farsang C, Klaene G, Lewis K, Manolis A, Perruchoud AP, Silagy C, van Spiegel PI, Astbury C, Hider A, Sweet R. Bupropion SR for smoking cessation in smokers with cardiovascular disease: a multicentre, randomised study. Eur Heart J 2003; 24: 946955.
  • 57
    Tashkin D, Kanner R, Bailey W, Buist S, Anderson P, Nides M, Gonzales D, Dozier G, Patel MK, Jamerson B. Smoking cessation in patients with chronic obstructive pulmonary disease: a double-blind, placebo-controlled, randomised trial. Lancet 2001; 357: 15711575.
  • 58
    Moore TJ, Furberg CD, Glenmullen J, Maltsberger JT, Singh S. Suicidal behavior and depression in smoking cessation treatments. PLoS ONE 2011; 6: e27016.
  • 59
    Wightman DS, Foster VJ, Krishen A, Richard NE, Modell JG. Meta-analysis of suicidality in placebo-controlled clinical trials of adults taking bupropion. Prim Care Companion J Clin Psychiatry 2010; 12: pii: PCC.09m00894.
  • 60
    Jimenez-Ruiz C, Berlin I, Hering T. Varenicline: a novel pharmacotherapy for smoking cessation. Drugs 2009; 69: 13191338.
  • 61
    Rollema H, Chambers LK, Coe JW, Glowa J, Hurst RS, Lebel LA, Lu Y, Mansbach RS, Mather RJ, Rovetti CC, Sands SB, Schaeffer E, Schulz DW, Tingley FD, Williams KE. Pharmacological profile of the alpha4beta2 nicotinic acetylcholine receptor partial agonist varenicline, an effective smoking cessation aid. Neuropharmacology 2007; 52: 985994.
  • 62
    Mihalak KB, Carroll FI, Luetje CW. Varenicline is a partial agonist at alpha4beta2 and a full agonist at alpha7 neuronal nicotinic receptors. Mol Pharmacol 2006; 70: 801805.
  • 63
    Tonstad S, Rollema H. Varenicline in smoking cessation. Expert Rev Respir Med 2010; 4: 291299.
  • 64
    Niaura R, Hays JT, Jorenby DE, Leone FT, Pappas JE, Reeves KR, Williams KE, Billing CB Jr. The efficacy and safety of varenicline for smoking cessation using a flexible dosing strategy in adult smokers: a randomized controlled trial. Curr Med Res Opin 2008; 24: 19311941.
  • 65
    Rennard S, Hughes J, Cinciripini PM, Kralikova E, Raupach T, Arteaga C, Aubin LB, Russ C. A randomized placebo-controlled trial of varenicline for smoking cessation allowing flexible quit dates. Nicotine Tob Res 2011; 14: 343350.
  • 66
    Nides M, Glover ED, Reus VI, Christen AG, Make BJ, Billing CB, Jr, Williams KE. Varenicline versus bupropion SR or placebo for smoking cessation: a pooled analysis. Am J Health Behav 2008; 32: 664675.
  • 67
    Cahill K, Stead LF, Lancaster T. Nicotine receptor partial agonists for smoking cessation. Cochrane Database Syst Rev 2012; (4): CD006103.
  • 68
    Aubin HJ, Bobak A, Britton JR, Oncken C, Billing CB, Jr, Gong J, Williams KE, Reeves KR. Varenicline versus transdermal nicotine patch for smoking cessation: results from a randomised open-label trial. Thorax 2008; 63: 717724.
  • 69
    Stapleton J, Watson L, Spirling LI, Smith R, Milbrandt A, Ratcliffe M, Sutherland G. Varenicline in the routine treatment of tobacco dependence: a pre-post comparison with nicotine replacement therapy and an evaluation in those with mental illness. Addiction 2007; 103: 146154.
  • 70
    Tonstad S, Tonnesen P, Hajek P, Williams KE, Billing CB, Reeves KR. Effect of maintenance therapy with varenicline on smoking cessation. JAMA 2006; 296: 6471.
  • 71
    Ebbert JO, Burke MV, Hays JT, Hurt RD. Combination treatment with varenicline and nicotine replacement therapy. Nicotine Tob Res 2009; 11: 572576.
  • 72
    Ebbert JO, Croghan IT, Sood A, Schroeder DR, Hays JT, Hurt RD. Varenicline and bupropion sustained-release combination therapy for smoking cessation. Nicotine Tob Res 2009; 11: 234239.
  • 73
    Mitchell JM, Teague CH, Kayser AS, Bartlett SE, Fields HL. Varenicline decreases alcohol consumption in heavy-drinking smokers. Psychopharmacology (Berl) 2012; 223: 299306.
  • 74
    Fucito LM, Toll BA, Wu R, Romano DM, Tek E, O'Malley SS. A preliminary investigation of varenicline for heavy drinking smokers. Psychopharmacology (Berl) 2011; 215: 655663.
  • 75
    Faessel HM, Smith BJ, Gibbs MA, Gobey JS, Clark DJ, Burstein AH. Single-dose pharmacokinetics of varenicline, a selective nicotinic receptor partial agonist, in healthy smokers and nonsmokers. J Clin Pharmacol 2006; 46: 991998.
  • 76
    Cahill K, Stead L, Lancaster T. A preliminary benefit-risk assessment of varenicline in smoking cessation. Drug Saf 2009; 32: 119135.
  • 77
    Ebbert JO, Wyatt KD, Hays JT, Klee EW, Hurt RD. Varenicline for smoking cessation: efficacy, safety, and treatment recommendations. Patient Prefer Adherence 2010; 4: 355362.
  • 78
    Leung LK, Patafio FM, Rosser WW. Gastrointestinal adverse effects of varenicline at maintenance dose: a meta-analysis. BMC Clin Pharmacol 2011; 11: 15.
  • 79
    Potts LA, Garwood CL. Varenicline: the newest agent for smoking cessation. Am J Health Syst Pharm 2007; 64: 13811384.
  • 80
    Moore TJ, Glenmullen J, Furberg CD. Prescription drugs associated with reports of violence towards others. PLoS ONE 2010; 5: e15337.
  • 81
    Kuehn BM. New reports examine psychiatric risks of varenicline for smoking cessation. JAMA 2012; 307: 129130.
  • 82
    Harrison-Woolrych M, Ashton J. Psychiatric adverse events associated with varenicline: an intensive postmarketing prospective cohort study in New Zealand. Drug Saf 2011; 34: 763772.
  • 83
    Tonstad S, Davies S, Flammer M, Russ C, Hughes J. Psychiatric adverse events in randomized, double-blind, placebo-controlled clinical trials of varenicline: a pooled analysis. Drug Saf 2010; 33: 289301.
  • 84
    Garza D, Murphy M, Tseng LJ, Riordan HJ, Chatterjee A. A double-blind randomized placebo-controlled pilot study of neuropsychiatric adverse events in abstinent smokers treated with varenicline or placebo. Biol Psychiatry 2011; 69: 10751082.
  • 85
    Gunnell D, Irvine D, Wise L, Davies C, Martin RM. Varenicline and suicidal behaviour: a cohort study based on data from the General Practice Research Database. BMJ 2009; 339: b3805.
  • 86
    FDA. FDA drug safety communication: safety review update of Chantix (varenicline) and risk of neuropsychiatric adverse events. 2011. Available at http://www.fda.gov/Drugs/DrugSafety/ucm276737.htm (last accessed 29 March 2013).
  • 87
    Covey LS, Berlin I, Hu MC, Hakes JK. Smoking and suicidal behaviours in a sample of US adults with low mood: a retrospective analysis of longitudinal data. BMJ Open 2012; 2: pii: e000876.
  • 88
    FDA. The smoking cessation aids varenicline (marketed as Chantix) and bupropion (marketed as Zyban and generics): suicidal ideation and behavior. FDA Drug Safety Newsletter 2009; 2; updated 2009. Available at http://www.fda.gov/Drugs/DrugSafety/DrugSafetyNewsletter/ucm110235.htm (last accessed 1 October 2010).
  • 89
    Singh S, Loke YK, Spangler JG, Furberg CD. Risk of serious adverse cardiovascular events associated with varenicline: a systematic review and meta-analysis. CMAJ 2011; 183: 13591366.
  • 90
    Prochaska JJ, Hilton JF. Risk of cardiovascular serious adverse events associated with varenicline use for tobacco cessation: systematic review and meta-analysis. BMJ 2012; 344: e2856.
  • 91
    George TP, O'Malley SS. Current pharmacological treatments for nicotine dependence. Trends Pharmacol Sci 2004; 25: 4248.
  • 92
    Aveyard P, Johnson C, Fillingham S, Parsons A, Murphy M. Nortriptyline plus nicotine replacement versus placebo plus nicotine replacement for smoking cessation: pragmatic randomised controlled trial. BMJ 2008; 336: 12231227.
  • 93
    Gourlay SG, Stead LF, Benowitz NL. Clonidine for smoking cessation. Cochrane Database Syst Rev 2008; (3): CD000058.
  • 94
    Lising-Enriquez K, George TP. Treatment of comorbid tobacco use in people with serious mental illness. J Psychiatry Neurosci 2009; 34: E12.
  • 95
    Lasser K, Boyd JW, Woolhandler S, Himmelstein DU, McCormick D, Bor DH. Smoking and mental illness: a population-based prevalence study. JAMA 2000; 284: 26062610.
  • 96
    Kalman D, Morissette SB, George TP. Co-morbidity of smoking in patients with psychiatric and substance use disorders. Am J Addict 2005; 14: 106123.
  • 97
    McCreadie RG. Use of drugs, alcohol and tobacco by people with schizophrenia: case-control study. Br J Psychiatry 2002; 181: 321325.
  • 98
    Williams JM, Ziedonis D. Addressing tobacco among individuals with a mental illness or an addiction. Addict Behav 2004; 29: 10671083.
  • 99
    Aubin HJ. Management of emergent psychiatric symptoms during smoking cessation. Curr Med Res Opin 2009; 25: 519525.
  • 100
    Hennekens CH, Hennekens AR, Hollar D, Casey DE. Schizophrenia and increased risks of cardiovascular disease. Am Heart J 2005; 150: 11151121.
  • 101
    Siru R, Hulse GK, Tait RJ. Assessing motivation to quit smoking in people with mental illness: a review. Addiction 2009; 104: 719733.
  • 102
    Fagerstrom K, Aubin HJ. Management of smoking cessation in patients with psychiatric disorders. Curr Med Res Opin 2009; 25: 511518.
  • 103
    George TP, Ziedonis DM, Feingold A, Pepper WT, Satterburg CA, Winkel J, Rounsaville BJ, Kosten TR. Nicotine transdermal patch and atypical antipsychotic medications for smoking cessation in schizophrenia. Am J Psychiatry 2000; 157: 18351842.
  • 104
    Tsoi DT, Porwal M, Webster AC. Efficacy and safety of bupropion for smoking cessation and reduction in schizophrenia: systematic review and meta-analysis. Br J Psychiatry 2010; 196: 346353.
  • 105
    Williams JM, Anthenelli RM, Morris CD, Treadow J, Thompson JR, Yunis C, George TP. A randomized, double-blind, placebo-controlled study evaluating the safety and efficacy of varenicline for smoking cessation in patients with schizophrenia or schizoaffective disorder. J Clin Psychiatry 2012; 73: 654660.
  • 106
    Yousefi MK, Folsom TD, Fatemi SH. A review of varenicline's efficacy and tolerability in smoking cessation studies in subjects with schizophrenia. J Addict Res Ther 2011; S4(1): pii: 3045.
  • 107
    Weiner E, Buchholz A, Coffay A, Liu F, McMahon RP, Buchanan RW, Kelly DL. Varenicline for smoking cessation in people with schizophrenia: a double blind randomized pilot study. Schizophr Res 2011; 129: 9495.
  • 108
    Shim JC, Jung DU, Jung SS, Seo YS, Cho DM, Lee JH, Lee SW, Kong BG, Kang JW, Oh MK, Kim SD, McMahon RP, Kelly DL. Adjunctive varenicline treatment with antipsychotic medications for cognitive impairments in people with schizophrenia: a randomized double-blind placebo-controlled trial. Neuropsychopharmacology 2011; 37: 660668.
  • 109
    Liu ME, Tsai SJ, Jeang SY, Peng SL, Wu SL, Chen MC, Tsai YL, Yang ST. Varenicline prevents affective and cognitive exacerbation during smoking abstinence in male patients with schizophrenia. Psychiatry Res 2011; 190: 7984.
  • 110
    McClure JB, Swan GE, Catz SL, Jack L, Javitz H, McAfee T, Deprey M, Richards J, Zbikowski SM. Smoking outcome by psychiatric history after behavioral and varenicline treatment. J Subst Abuse Treat 2010; 38: 394402.
  • 111
    Kinnunen T, Doherty K, Militello FS, Garvey AJ. Depression and smoking cessation: characteristics of depressed smokers and effects of nicotine replacement. J Consult Clin Psychol 1996; 64: 791798.
  • 112
    Aubin HJ, Berlin I, Reynaud M. Early life origins of adult disease and maternal smoking during pregnancy. Am J Public Health 2012; 102: e12.
  • 113
    Oncken CA, Kranzler HR. What do we know about the role of pharmacotherapy for smoking cessation before or during pregnancy? Nicotine Tob Res 2009; 11: 12651273.
  • 114
    Grange G, Vayssiere C, Borgne A, Ouazana A, L'Huillier JP, Valensi P, Peiffer G, Aubin HJ, Renon D, Thomas D, Lebargy F. Description of tobacco addiction in pregnant women. Eur J Obstet Gynecol Reprod Biol 2005; 120: 146151.
  • 115
    Coleman T, Chamberlain C, Cooper S, Leonardi-Bee J. Efficacy and safety of nicotine replacement therapy for smoking cessation in pregnancy: systematic review and meta-analysis. Addiction 2011; 106: 5261.
  • 116
    Coleman T, Cooper S, Thornton JG, Grainge MJ, Watts K, Britton J, Lewis S. A randomized trial of nicotine-replacement therapy patches in pregnancy. N Engl J Med 2012; 366: 808818.
  • 117
    Pirie K, Peto R, Reeves GK, Green J, Beral V. The 21st century hazards of smoking and benefits of stopping: a prospective study of one million women in the UK. Lancet 2012; 381: 133141.
  • 118
    Herman AI, Sofuoglu M. Comparison of available treatments for tobacco addiction. Curr Psychiatry Rep 2010; 12: 433440.
  • 119
    Bronisch T, Hofler M, Lieb R. Smoking predicts suicidality: findings from a prospective community study. J Affect Disord 2008; 108: 135145.
  • 120
    Kim Y, Myung SK, Jeon YJ, Lee EH, Park CH, Seo HG, Huh BY. Effectiveness of pharmacologic therapy for smoking cessation in adolescent smokers: meta-analysis of randomized controlled trials. Am J Health Syst Pharm 2011; 68: 219226.
  • 121
    Bailey SR, Crew EE, Riske EC, Ammerman S, Robinson TN, Killen JD. Efficacy and tolerability of pharmacotherapies to aid smoking cessation in adolescents. Paediatr Drugs 2012; 14: 91108.
  • 122
    Etter JF. Cytisine for smoking cessation. Arch Intern Med 2006; 166: 15531559.
  • 123
    Tutka P, Zatonski W. Cytisine for the treatment of nicotine addiction: from a molecule to therapeutic effcacy. Pharmacol Rep 2005; 58: 777798.
  • 124
    West R, Zatonski W, Cedzynska M, Lewandowska D, Pazik J, Aveyard P, Stapleton J. Placebo-controlled trial of cytisine for smoking cessation. N Engl J Med 2011; 365: 11931200.
  • 125
    Walker N, Howe C, Bullen C, McRobbie H, Glover M, Parag V, Williman J, Veale R, Nosa V, Barnes J. Study protocol for a non-inferiority trial of cytisine versus nicotine replacement therapy in people motivated to stop smoking. BMC Public Health 2011; 11: 880.
  • 126
    Tonstad S, Holme I, Tonnesen P. Dianicline, a novel {alpha}4{beta}2 nicotinic acetylcholine receptor partial agonist, for smoking cessation: a randomized placebo-controlled clinical trial. Nicotine Tob Res 2010; 13: 16.
  • 127
    George TP, Weinberger AH. Monoamine oxidase inhibition for tobacco pharmacotherapy. Clin Pharmacol Ther 2008; 83: 619621.
  • 128
    Berlin I, Anthenelli RM. Monoamine oxidase and tobacco smoking. Int J Neuropsychopharmacol 2001; 4: 3342.
  • 129
    Berlin I, Said S, Spreux-Varoquaux O, Olivares R, Launay JM, Puech AJ. Monoamine oxidase A and B activities in heavy smokers. Biol Psychiatry 1995; 38: 756761.
  • 130
    Berlin I, Said S, Spreux-Varoquaux O, Launay JM, Olivares R, Millet V, Lecrubier Y, Puech AJ. A reversible monoamine oxidase A inhibitor (moclobemide) facilitates smoking cessation and abstinence in heavy, dependent smokers. Clin Pharmacol Ther 1995; 58: 444452.
  • 131
    Berlin I, Aubin HJ, Pedarriosse AM, Rames A, Lancrenon S, Lagrue G. Lazabemide, a selective, reversible monoamine oxidase B inhibitor, as an aid to smoking cessation. Addiction 2002; 97: 13471354.
  • 132
    Weinberger AH, Reutenauer EL, Jatlow PI, O'Malley SS, Potenza MN, George TP. A double-blind, placebo-controlled, randomized clinical trial of oral selegiline hydrochloride for smoking cessation in nicotine-dependent cigarette smokers. Drug Alcohol Depend 2010; 107: 188195.
  • 133
    Killen JD, Fortmann SP, Murphy GM, Jr, Hayward C, Fong D, Lowenthal K, Bryson SW, Killen DT, Schatzberg AF. Failure to improve cigarette smoking abstinence with transdermal selegiline + cognitive behavior therapy. Addiction 2010; 105: 16601668.
  • 134
    Berlin I, Hunneyball IM, Greiling D, Jones SP, Fuder H, Stahl HD. A selective reversible monoamine oxidase B inhibitor in smoking cessation: effects on its own and in association with transdermal nicotine patch. Psychopharmacology (Berl) 2012; 223: 8998.
  • 135
    Raupach T, van Schayck CP. Pharmacotherapy for smoking cessation: current advances and research topics. CNS Drugs 2011; 25: 371382.
  • 136
    Cerny EH, Cerny T. Vaccines against nicotine. Hum Vaccin 2009; 5: 200205.
  • 137
    Nabi biopharmaceuticals announces results of second NicVAX(R) phase III clinical trial. 2011. Available at http://phx.corporate-ir.net/phoenix.zhtml?c=100445&p=irol-newsArticle&ID=1626882&highlight= (last accessed 27 June 2012).
  • 138
    Jackson A, Nesic J, Groombridge C, Clowry O, Rusted J, Duka T. Differential involvement of glutamatergic mechanisms in the cognitive and subjective effects of smoking. Neuropsychopharmacology 2009; 34: 257265.
  • 139
    Shinn AK, Greenfield SF. Topiramate in the treatment of substance-related disorders: a critical review of the literature. J Clin Psychiatry 2010; 71: 634648.
  • 140
    Anthenelli RM, Blom TJ, McElroy SL, Keck PE, Jr. Preliminary evidence for gender-specific effects of topiramate as a potential aid to smoking cessation. Addiction 2008; 103: 687694.
  • 141
    Baltieri DA, Daro FR, Ribeiro PL, Andrade AG. Effects of topiramate or naltrexone on tobacco use among male alcohol-dependent outpatients. Drug Alcohol Depend 2009; 105: 3341.
  • 142
    Johnson BA, Ait-Daoud N, Akhtar FZ, Javors MA. Use of oral topiramate to promote smoking abstinence among alcohol-dependent smokers. Arch Intern Med 2005; 165: 16001605.
  • 143
    Franklin TR, Harper D, Kampman K, Kildea-McCrea S, Jens W, Lynch KG, O'Brien CP, Childress AR. The GABA B agonist baclofen reduces cigarette consumption in a preliminary double-blind placebo-controlled smoking reduction study. Drug Alcohol Depend 2009; 103: 3036.
  • 144
    White WD, Crockford D, Patten S, El-Guebaly N. A randomized, open-label pilot comparison of gabapentin and bupropion SR for smoking cessation. Nicotine Tob Res 2005; 7: 809813.
  • 145
    Sood A, Ebbert JO, Wyatt KD, Croghan IT, Schroeder DR, Sood R, Hays JT. Gabapentin for smoking cessation. Nicotine Tob Res 2010; 12: 300304.
  • 146
    Sood A, Ebbert JO, Schroeder DR, Croghan IT, Sood R, Vander Weg MW, Wong GY, Hays JT. Gabapentin for smoking cessation: a preliminary investigation of efficacy. Nicotine Tob Res 2007; 9: 291298.
  • 147
    Evins AE, Pachas G, Mischoulon D, Urbanoski K, Carlini S, Sousa J, Bentley K, Rigotti NA, Nino-Gomez J, Loebl T, Janes AC, Kaufman MJ, Fava M. A double-blind, placebo-controlled trial of the NMDA glycine site antagonist, GW468816, for prevention of relapse to smoking in females. J Clin Psychopharmacol 2011; 31: 597602.
  • 148
    Schmaal L, Berk L, Hulstijn KP, Cousijn J, Wiers RW, van den Brink W. Efficacy of N-acetylcysteine in the treatment of nicotine dependence: a double-blind placebo-controlled pilot study. Eur Addict Res 2011; 17: 211216.
  • 149
    Ballon JS, Feifel D. A systematic review of modafinil: potential clinical uses and mechanisms of action. J Clin Psychiatry 2006; 67: 554566.
  • 150
    Dackis CA, Kampman KM, Lynch KG, Pettinati HM, O'Brien CP. A double-blind, placebo-controlled trial of modafinil for cocaine dependence. Neuropsychopharmacology 2005; 30: 205211.
  • 151
    Lerman C, Roth D, Kaufmann V, Audrain J, Hawk L, Liu A, Niaura R, Epstein L. Mediating mechanisms for the impact of bupropion in smoking cessation treatment. Drug Alcohol Depend 2002; 67: 219223.
  • 152
    Schnoll RA, Wileyto EP, Pinto A, Leone F, Gariti P, Siegel S, Perkins KA, Dackis C, Heitjan DF, Berrettini W, Lerman C. A placebo-controlled trial of modafinil for nicotine dependence. Drug Alcohol Depend 2008; 98: 8693.
  • 153
    Le Foll B, Sokoloff P, Stark H, Goldberg SR. Dopamine D3 receptor ligands block nicotine-induced conditioned place preferences through a mechanism that does not involve discriminative-stimulus or antidepressant-like effects. Neuropsychopharmacology 2005; 30: 720730.
  • 154
    McNeill A, Raw M, Whybrow J, Bailey P. A national strategy for smoking cessation treatment in England. Addiction 2005; 100: (Suppl. 2): 111.
  • 155
    Agboola S, McNeill A, Coleman T, Leonardi Bee J. A systematic review of the effectiveness of smoking relapse prevention interventions for abstinent smokers. Addiction 2010; 105: 13621380.
  • 156
    Hajek P, Stead LF, West R, Jarvis M, Lancaster T. Relapse prevention interventions for smoking cessation. Cochrane Database Syst Rev 2009; (1): CD003999.
  • 157
    Borland R, Partos TR, Cummings KM. Systematic biases in cross-sectional community studies may underestimate the effectiveness of stop-smoking medications. Nicotine Tob Res 2012; 14: 14831487.
  • 158
    Pollock JD, Koustova E, Hoffman A, Shurtleff D, Volkow ND. Treatments for nicotine addiction should be a top priority. Lancet 2009; 374: 513514.